INTRODUCTORY LECTURE
Carsten FLOHR
St John’s Institute of Dermatology
King’s College London
on behalf of the SECURE-AS Study Team
London, United Kingdom
Overview
- Video presentation
- Presentation
- Full version download as PDF
- Ask questions to the author
Author retain copyright.
VIDEO RECORDING
PRESENTATION
Why a COVID registry for AD patient?
SECURE-AD Study Team
International Scientific Advisory Committee
- Sébastien Barbarot MD PhD, France (ETFAD)
- Esther Freeman MD PhD, USA (AAD/ILDS COVID-19 registry)
- Emma Guttman MD PhD, USA (IEC)
- Jo Lambert MD PhD, Belgium (SPIN)
- Tamar Nijsten MD PhD, The Netherlands (EDEN)
- Amy Paller MD, USA (IEC)
- Carle Paul MD PhD, France (EADV)
- Alain Taïeb MD PhD, France (ISAD)
- Andreas Wollenberg MD PhD, Germany (ISAD/ETFAD)
- Christian Vestergaard MD PhD, Denmark (ETFAD)
- Andrea Chiricozzi MD, Italy (DA-COVID 19)
- Ketty Peris MD, Italy (DA-COVID 19)
Physician-reported AD severity
AD systemic treatments
COVID-19 infection outcome data
Italian DA-COVID registry
Other evidence
Conclusions
- The risk of COVID and its complications appears low overall in AD patients treated with systemics (but avoid oral corticosteroids at high doses)
- Potential signal for hospital attendances with conventional immunosuppressives vs dupilumab (cave: confounders, larger n needed)
- More data on conventional immuno-suppressives needed
- Registries not necessarily representative of AD patients at large
- Other population-based study designs are more suitable to answer some important questions (primary care electronic health records and national registry data) – overall risk of COVID in AD patients vs healthy individuals
Related COVID registries
Comparative analyses
SECURE-AD Partner Dermatology Societies/Organisations
SECURE-AD Patient Partner Organisations
Thank you for your attention
Everybody who enters a case will be included as a co-author under the SECURE-AD Study Group in resulting publications.
Ask questions to Carsten FLOHR:
[contact-form-7 id=”3756″ title=”Ask question LIVE”]
Conflict of interest :
- Partly supported by the National Institute for Health Research Biomedical
- Research Centre (NIHR BRC) at Guy’s and St Thomas’ Hospitals, London
- CI TREatment of severe atopic eczema Trial (TREAT)
- CI UK-Irish Atopic eczema Systemic Therapy Register (A-STAR)
- Co-Lead International TREAT Registry Task Force
- PI EU Horizon 2020 IMI programme BIOMAP
- Co-Lead SECURE-AD registry
- Microbiome research programme partly funded by Sanofi (iAwards Europe)
- No consultancy/lectures with honoraria
- No stocks/options